Investors
-
May 20, 2025Notice to attend the Annual General Meeting in Umecrine Cognition ABSTOCKHOLM – May 20, 2025. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general...
-
May 7, 2025Umecrine Cognition to present a novel clinically validated symptom severity scale in Primary Biliary Cholangitis at EASL 2025STOCKHOLM – May 7, 2025. Umecrine Cognition today announces that the company will present validation and implementation data for the newly...
-
May 5, 2025Umecrine Cognition receives a grant from The Michael J. Fox Foundation to support preclinical evaluation of golexanolone in Parkinson’s diseaseSTOCKHOLM – May 5, 2025. Umecrine Cognition today announces that the company has been awarded a research grant by The Michael J. Fox Foundation for...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.